With this funding, Agatsa will scale up its operations and marketing along with expanding its global
Speaking about this, Mr. Rahul Rastogi & Ms. Neha Rastogi, Co-Founders, Agatsa, said, “Our first line of products under the label SanketLife are aimed at addressing the delay in getting cardiac care post the appearance of a symptom. Going forward, we plan to create a range of products including wearables that help in the timely diagnosis and management of non-communicable diseases. Our AI capabilities make us one of the very few companies in the world to have implemented the procedures and variables under the Minnesota Code. We are delighted to get IAN & TDB on board as investors and will leverage the capital infusion to bolster our platform, build a robust network of doctors, and find innovative ways to further reduce the response time.”
“There is an essential requirement to develop cutting-edge technology based Medical Devices indigenously, that are easy-to-use, affordable and accessible even in the far-flung areas of the Indian sub-continent. Agatsa Software Pvt Ltd is set to play a crucial role in achieving this objective. Technology Development Board (TDB) recognizes excellence in individuals and organizations for contributing to the development and commercialization of indigenous technologies. TDB is pleased to support SanketLife project by Agatsa, a start-up company which commenced its journey as a Department of Science & Technology (DST) supported incubatee. TDB wishes Agatsa’s team all the very best in their quest to manufacture advanced and affordable healthcare devices domestically,” representatives of the Technology Development Board (TDB), Government of India said in an official statement.
In a short span, Agatsa has recorded ECG readings for over 100,000 users and more than 6,000 doctors are using the SanketLife devices. These devices are clinically validated to have 98% accuracy compared to traditional ECG devices and provide swift reports that are authenticated and reviewed by doctors within 10 minutes. Going forward, Agatsa is planning to introduce a wearable device offering early detection of 17 different diseases such as diabetes, epilepsy, obesity, anxiety, and neuropathy, etc.
Agatsa has cracked partnership deals with various B2B clients, offering emergency response to elderly population and cardiac patients. The start-up further plans to bolster its service portfolio by integrating an emergency ECG review services into the Agatsa app to ensure seamless cardiac support to B2B users like hospitals, PHCs, Polyclinics etc. The start-up will also expand into other devices that help in the management of other non-communicable diseases like blood pressure, diabetes etc.
About Agatsa:Agatsa, India’s most agile health solutions innovator is a technology-driven company